TriSalus Life Sciences, Inc. (TLSI)

Market Cap	223.52M -1.3%
Revenue (ttm)	45.08M +25.2%
Net Income	-57.25M
EPS	-1.15
Shares Out	61.57M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	253,519
Open	3.830
Previous Close	3.900
Day's Range	3.580 - 3.900
52-Week Range	2.200 - 7.950
Beta	0.47
Analysts	Strong Buy
Price Target	10.40 (+186.5%)
Est. Earnings	Nov 12, 2026

About TLSI

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 102
• Stock Exchange: Nasdaq
• Ticker Symbol: TLSI
• Website: https://trisaluslifesci.com

Financial Performance

In 2025, TriSalus Life Sciences's revenue was $45.15 million, an increase of 53.41% compared to the previous year's $29.43 million. Losses were -$69.69 million, 109.7% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price target is $10.4, which is an increase of 186.50% from the latest price.

Price Target

$10.4

(186.50% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 17, 2026

Data Sources Report a data error